Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

Trial status:Study Complete
Trial ID:
BNT162-03
NCT ID:
NCT04523571
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Study Complete

Trial Details

This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.

Medical Condition
  • COVID-19
    • Trial Drug
  • BNT162b1
    • Phase
    Phase 1
    Type
    Interventional
    Estimated Enrolment
    144
    Estimated Trial Date
    Jul 2020 - Sep 2020

    Trial Participant Requirements

    Age
    18 - 85 Years
    Sex
    Female & Male
    Healthy Volunteers
    Yes

    Trial Locations

    Location
    Status
    Location
    Jiangsu Provincial Center for Disease Control and Prevention
    Taizhou, Jiangsu, China, 210009
    Status